Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1 investigator-initiated trial of eftilagimod alpha in conjunction with pembrolizumab plus doublet chemotherapy (carboplatin and pemetrexed) in patients with various solid tuumours

Next Previous
X
Search
Trial Profile

Phase 1 investigator-initiated trial of eftilagimod alpha in conjunction with pembrolizumab plus doublet chemotherapy (carboplatin and pemetrexed) in patients with various solid tuumours

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 02 Aug 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Carboplatin (Primary) ; Eftilagimod alpha (Primary) ; Pembrolizumab (Primary) ; Pemetrexed (Primary)
  • Indications Adenocarcinoma; Non-small cell lung cancer; Solid tumours
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Acronyms INSIGHT-003

    • Most Recent Events

    • 31 Jul 2024 According to an Immutep Limited media release, this trial continued to enrol patients throughout the quarter, with 43 out of a target of 50 patients enrolled and safely dosed across six sites in Germany. Further updates from INSIGHT-003 will be provided in CY2024.
    • 29 Apr 2024 According to an Immutep Limited media release, 38 out of a total of 50 patients have been enrolled and safely dosed across six sites in Germany.
    • 22 Nov 2023 According to an Immutep Limited media release, the extension opened in mid-2023 and 29 patients have been enrolled to date. With the addition of the new sites, the trial is expected to complete recruitment in 1H CY2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top